CBD Corneal-Pain Findings in Mice Included a Serotonin-Receptor Blockade Test

forensic toxicology working group members October 31, 2026 Forensic Toxicology

A mouse corneal-injury study summarized in an ocular CBD review found lower pain scores and less inflammatory-cell infiltration. Blocking a serotonin receptor interfered with these effects, supporting a mechanism to investigate rather than an established human eye treatment.

The injury and challenge were experimental

The study used silver-nitrate cauterization of mouse corneas followed by a capsaicin pain challenge. CBD-treated animals had lower pain scores, and their corneas showed less neutrophil infiltration. These are separate behavioral and tissue findings in an induced injury model. They do not establish relief of every cause of ocular pain or preservation of human vision.

The antagonist added mechanistic evidence

The review reports that WAY100635, a 5-HT1A antagonist, blocked CBD’s effects. This supports involvement of that signaling pathway under the tested conditions. It does not identify every downstream process or establish that the same mechanism dominates after oral CBD in patients. The local preparation and experimental route remain part of the result.

Translation requires an appropriate formulation and outcome

A clinical claim would require evidence that a defined preparation reaches the relevant tissue, improves patient outcomes and has acceptable ocular safety. The review supplies no basis for putting an ordinary CBD oil in the eye. Its useful contribution is a specific preclinical link among corneal injury, pain behavior, inflammation and receptor signaling, with the human therapeutic step still unresolved.

Related analysis: the broader review findings and limitations.